LAPAROSCOPIC POWER MORCELLATORS MARKET ANALYSIS

Laparoscopic power morcellators are Class II medical devices that cut tissue into smaller pieces so that it can be removed through a small incision site during laparoscopic (minimally invasive) procedures. They are primarily used for procedures such as hysterectomy and myomectomy. These morcellators are used in surgeries for removing gallbladder, kidneys, liver, and spleen. These are majorly used in two operational procedures such as hysterectomy (the surgical removal of a woman's uterus), and myomectomy (the surgical removal of uterine fibroids), which are benign tumor growths in the uterus, are two other procedures. The increasing prevalence of uterus fibroid due to various causes such as cancer, polyps, endometriosis, fibroids, and adenomyosis, is projected to drive the growth of the laparoscopic power morcellators market.

Global Laparoscopic Power Morcellators Market - Impact of the Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic is expected to hamper the growth of the global laparoscopic power morcellators market over the forecast period owing to the delaying of medical surgeries. For instance, on July 6, 2021, PLOS one, a scientific journal for science and medicine, has published study on the impact of the COVID-19 pandemic on waiting times for elective surgery patients. Where the study concluded that the health care service providers patients will have increased elective surgery waiting times by one-third due to the pandemic, however the elective surgery rate will increase by one-fifth after the pandemic. This shows a drop in the usage of laparoscopic power morcellators, which could have a negative impact on the market growth.

The global laparoscopic power morcellators market is estimated to be valued at US$ 102.1 Mn in 2021 and is expected to exhibit a CAGR of 5.3% over the forecast period (2021-2028).  

Figure 1: Global Laparoscopic Power Morcellators Market Share, (%), Analysis, By Application, 2021

Increasing prevalence of Uterine Leiomyomata (UL) in women is expected to drive the growth of the global laparoscopic power morcellators market over the forecast period.

Increasing prevalence of uterine fibroids in women; will in turn increase the adoption of laparoscopic power morcellators which is expected to drive the growth of the global laparoscopic power morcellators market over the forecast period. For instance, According to the article published in August 2021, the prevalence and burden of symptomatic uterine leiomyomata which is also called as fibroids and benign tumors of the uterus among women was approximately 1 in 20 or 5% or 13.6 million people globally.

Market players are indulged in following guidelines issued by regulatory authorities to receive 510 (k) clearance for the products such as laparoscopic power morcellators, which is expected to drive the growth of the global laparoscopic power morcellators market over the forecast period.

Companies are focused on developing new laparoscopic power morcellators with 510 (k) product clearance based on new regulatory guidelines from the regulatory authorities which is expected to drive the growth of the global laparoscopic power morcellators market over the forecast period. For instance, on February 3, 2021, Olympus America indicated that it supported the U.S. Food and Drug Administration (FDA) published guidance recommendations suggesting that laparoscopic power morcellators in gynecological procedures must be performed using an approved containment device. Olympus is now the sole manufacturer having a 510(k)-cleared containment laparoscopic power morcellation device in the U.S.

Global Laparoscopic Power Morcellators Market – Restraints

The product recall from the regulatory authorities is expected to hamper the growth of the global laparoscopic power morcellators market over the forecast period. For instance, on October 26, 2021, the U.S. Food and Drug Administration (US FDA) issued a recall notice for the PneumoLiner device which is intended for use as a tissue containment system during minimally invasive gynecologic laparoscopic surgery, manufactured by Olympus Corporation of the Americas has received recall notification from the U.S. Food and Drug Administration (FDA) due to manufacturing error.

Global Laparoscopic Power Morcellators Market – Regional Analysis

On the basis of region, the global laparoscopic power morcellators market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Among regions, North America is expected to hold a dominant position during forecast period in laparoscopic power morcellators market, owing to the increasing prevalence of uterine cancer. For instance, in the U.S., 66,570 women are predicted to be diagnosed with uterine cancer, commonly known as endometrial cancer in 2021, according to the American Society of Clinical Oncology (ASCO). In the U.S., uterine cancer is the fourth most frequent cancer and sixth highest cause of mortality among women. As of 2021, there were over 600,000 uterine cancer survivors in the U.S. which thereby increases the demand for uterine cancer treatment. As a result of the rising prevalence of uterine cancer, demand for myomectomy and hysterectomy procedures is rising globally, which is expected to drive the growth of laparoscopic power morcellators market over the forecast period.

Figure 2: Global Laparoscopic Power Morcellators Market (US$ Mn), by Region, 2021

Global Laparoscopic Power Morcellators Market – Competitive Landscape

Major players operating in the global laparoscopic power morcellators market include LiNA medical, Blue endo, Johnson and Johnson, Endomedium, Hangzhou kangji medical instruments, WISAP medical technology, Zhejiang geyi medical instrument, Karl storz GmbH, Medtronic, Richard wolf GmbH, Lumenis (Boston Scientific Corporation), Nouvag AG, RUDOLF Medical GmbH, and Olympus Corporation.